Waldstreicher Joanne 4

What Happened

• Joanne Waldstreicher, a director of Structure Therapeutics (GPCR), received a grant of 39,453 derivative shares (award) on June 17, 2026. The filing reports an acquisition price of $0 because this is a grant/award (derivative), not an open-market purchase or sale.
• The footnotes state the option exercise price per share equals the fair market value of the Issuer’s Ordinary Shares on the grant date (based on ADS trading price). The Ordinary Shares may be represented by ADSs, where each ADS equals three Ordinary Shares.

Key Details

• Transaction date: June 17, 2026; Form 4 filed June 18, 2026 (timely).
• Reported amount: 39,453 derivative shares; reported acquisition price $0 (derivative award).
• Vesting: Shares vest in equal monthly installments over the 12 months after June 17, 2026, and in any event will be fully vested immediately prior to the Issuer’s 2027 annual meeting (Footnote F2).
• Exercise price: Equal to fair market value per Ordinary Share on grant date (Footnote F1).
• ADS conversion: Each ADS represents three Ordinary Shares (Footnote F3).
• Shares owned after transaction: not specified in the provided filing.

Context

• This was a grant/award (derivative), not a purchase or sale; such awards are common for directors and do not necessarily signal a personal cash investment. The reported $0 acquisition value reflects the nature of the grant; actual economic value depends on vesting and future share/ADS prices and the stated exercise price.